ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

7,683Medicare Part D Prescriptions Filled, Including Refills

Rank: 40 out of 623

$452K Total Retail Price of All Prescriptions

Rank: 51 out of 623

370 Patients Receiving at Least One Drug in Part D
85%Patients 65 Years and Older
29% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Maryland
Lower avg

Schedule Two
Controlled Substances

3% of this provider’s 370 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

3% of this provider’s 370 patients filled at least one prescription for a schedule three drug, compared to an average of 5%.

Risky Drugs to Seniors

1% of this provider’s 6,213 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

20% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$59 was the average price of a prescription from this provider, compared to $66 among peers.

Prescriptions per Patient

21 is the average number of prescriptions (including refills) per patient, compared to an average of 16.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Maryland
LISINOPRIL 370 291 1 1
OMEPRAZOLE 290 188 2 7
SIMVASTATIN 287 244 3 2
LEVOTHYROXINE SODIUM 239 194 4 4
METOPROLOL TARTRATE 238 207 5 9
AMLODIPINE BESYLATE 235 205 6 3
LOVASTATIN 203 172 7 25
ATORVASTATIN CALCIUM 186 165 8 10
HYDROCHLOROTHIAZIDE 178 165 9 8
METFORMIN HCL 177 143 10 6
TRAMADOL HCL 174 153 11 15
CITALOPRAM HBR 155 134 12 21
SERTRALINE HCL 154 103 13 20
PRAVASTATIN SODIUM 134 127 14 11
FUROSEMIDE 129 113 15 5
WARFARIN SODIUM 122 119 16 14
ZOLPIDEM TARTRATE 102 59 17 22
DONEPEZIL HCL 97 93 18 27
GEMFIBROZIL 88 56 19 110
METOPROLOL SUCCINATE 87 80 20 13
FLUTICASONE PROPIONATE 79 40 21 29
ALENDRONATE SODIUM 75 50 22 37
GABAPENTIN 74 37 23 18
LISINOPRIL-HYDROCHLOROTHIAZIDE 71 56 24 19
LOSARTAN-HYDROCHLOROTHIAZIDE 70 70 25 59
DIOVAN 69 69 26 48
LANTUS 67 53 27 41
ATENOLOL 66 62 28 12
PAROXETINE HCL 64 52 29 66
RANITIDINE HCL 64 32 29 23
TRIAMTERENE-HCTZ 63 47 31 74
LOSARTAN POTASSIUM 62 62 32 16
CLONIDINE HCL 60 53 33 55
NEXIUM 58 45 34 43
ZETIA 57 57 35 99
METFORMIN HCL ER 53 51 36 56
MELOXICAM 52 46 37 50
CYMBALTA 51 32 38 52
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Oct. 16, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.